Anaplastic large-cell lymphoma (ALCL) is a distinct biological and cytogenetic entity with a broad spectrum of morphological features (common type, small-cell variant and lymphohistiocytic variant). Few cell lines of ALCL are available and they all originate from primary tumors demonstrating the common type morphology (ie large-sized lymphoma cells). We established a new ALCL cell line (COST) from the peripheral blood of a patient with a small-cell variant of ALCL, at diagnosis. Cells growing in vitro and in SCID mice consisted of two populations, that is, small-and large-sized cells as seen in the patient's tumor. Both large and small malignant cells were positive for CD43/MT1 T-cell associated antigen, perforin, granzyme B and TIA-1, but negative for CD2, CD3, CD5, CD7, CD4 and CD8 antigens. Standard cytogenetic studies as well as multiplex FISH confirmed the presence of the canonical t(2;5)(p23;q35) translocation, but also revealed additional numerical and structural abnormalities. The COST cell line is the first ALCL small-cell variant cell line, and thus provides a potentially useful tool for further functional and molecular studies that should improve our understanding of the small-cell variant of ALCL, which is more frequently complicated by a leukemic phase.
Introduction
Anaplastic large-cell lymphomas (ALCL), first described in 1985, 1 are high-grade lymphomas of T or null phenotype. They are frequently associated with a reciprocal chromosomal translocation t(2;5)(p23;q35), involving the tyrosine kinase gene ALK (2p23) and the nucleophosmin gene NPM (5q35). 2 This translocation results in the expression of a chimeric protein consisting of the N-terminal portion of NPM and the entire cytoplasmic tyrosine kinase domain of ALK. Although these lymphomas have distinct morphological, phenotypical and cytogenetic features and constitute a well-defined entity, they show a broad spectrum of morphological subtypes including common type, lymphohistiocytic and small cell variants. [3] [4] [5] [6] [7] [8] [9] The small-cell variant is characterized by a predominant population of small cells with only scattered large cells ('hallmark cells'). These latter cells are often concentrated around small blood vessels. 5, 7 The morphological variants of ALCL are sufficiently diverse to suggest that they may be associated with important biological differences not currently understood. All previous ALCL cell lines have been developed from primary tumors demonstrating the common type morphology. In this report, we describe a new ALCL cell line (COST), established from the peripheral blood of a patient with a small-cell variant of ALCL, at the time of diagnosis. Cells growing in vitro and in SCID mice consisted of two populations, that is, small and large lymphoid cells similar to the patient's primary tumor. To the best of our knowledge, this cell line is the first ALCL small-cell variant cell line to be established and thus provides a potentially useful tool for further functional and molecular studies of ALCL.
Materials and methods

Case report and immunohistochemical findings
The patient was a 4-year-old boy who presented with inguinal lymphadenopathy and interstitial pneumonia. Histopathological examination of the lymph node showed a lymphoproliferation consisting of cells of varying sizes, admixed in some areas with large numbers of histiocytes. Tumor cells were predominantly small-or medium-sized lymphocytes with irregular nuclei, but a minor population of large cells was also present, either scattered among the small cells or around blood vessels. Morphological characteristics of some large cells included eccentric kidney-shaped nuclei, corresponding to the 'hallmark cells' previously described in typical ALCL. 7 Immunohistochemistry on paraffin sections showed that neoplastic cells coexpressed CD30 and epithelial membrane antigen (EMA). Malignant cells stained positively for CD43 (MT1), TIA-1, perforin and granzyme B, but were negative for T-cell-associated markers CD2, CD3, CD4, CD5, CD7 and CD8. Small-and large-sized neoplastic cells were strongly positive for ALK1 antibody. 10 However, large neoplastic cells showed cytoplasmic, nuclear and nucleolar staining pattern, whereas ALK staining was mostly nuclear in the small-cell population. On the basis of previous reports, this ALK staining pattern suggested an association with the t(2;5) and the expression of NPM-ALK fusion protein. 9, 11 The association with the t(2;5) translocation was further confirmed by karyotypic analysis and reverse-transcription polymerase chain reaction (RT-PCR) using NPM and ALK specific primers. 12 Bone marrow was involved at the time of diagnosis, as shown by scattered CD30, EMA and ALK1-positive malignant cells. A sample of peripheral blood was also collected for cell culture and detection of t(2;5)-bearing lymphocytes. RT-PCR analysis using NPM and ALK primers revealed the presence of t(2;5)-positive malignant cells in peripheral blood, at the time of diagnosis. After 1 month, the patient developed small erythematous papules arising on the trunk. A skin biopsy showed neoplastic infiltrates in a perivascular and periappendageal distribution. A complete remission was achieved with intensive chemotherapy including vincristine, cyclophosphamide and prednisone (according to the protocol of Société Française d'Oncologie Pédiatrique). The patient is still in complete remission 44 months following the diagnosis.
Establishment of the cell line
Tumor cell preparation: Peripheral mononuclear blood cells containing circulating tumor cells were isolated from the peripheral blood of the patient, at the time of diagnosis, in 1998, by gradient centrifugation using Ficoll-Lymphoprep (Invitrogen, Cergy Pontoise, France), washed once in RPMI 1640 (Invitrogen, Cergy Pontoise, France) and cultured in ISCOVE medium (Invitrogen, Cergy Pontoise, France) supplemented with 20% fetal calf serum (FCS), penicillin, streptomycin, and L-glutamine at 371C in a 5% CO 2 humidified environment. Because of difficulties in maintaining the cell line in culture, we elected to xenograft cultured cells into SCID mice.
Xenograft to SCID mice
Animals: SCID mice, 6-8 weeks old, were obtained from Iffa-Credo (L'Arbresle, Lyon, France) and housed in autoclaved micro-isolator cages with an air-filtred laminar flow cabinet within the Service de Zootechnie (IFR30, Toulouse, France). Food was irradiated prior to animal feeding. Water and bedding were autoclaved before use. All procedures were performed under aseptic conditions. Cultured cells (10 Â 10 6 cells) were injected subcutaneously into the flank of two SCID mice.
Morphological and phenotypical analyses
For routine histopathological examination, tumor tissue was fixed in 10% buffered formalin and embedded in paraffin. Immunohistochemistry was performed using the streptavidinbiotin-peroxidase complex (ABC) method with the Dako StreptABComplex/HRP Duet (Mouse/Rabbit) kit (Dako, Code No. K492). Several monoclonal antibodies were used to identify antigens expressed by tumor cells (see Table 1 ).
Cell culture and immunophenotyping of COST cell line
A fragment of fresh tissue from the tumor growing in one SCID mouse was minced with a scapel blade and incubated in basal ISCOVE medium supplemented with 20% fetal calf serum, penicillin (50 U/ml), streptomycin (50 mg/ml), sodium pyruvate (1 mM), and L-glutamine (2 mM) at 371C in a humidified atmosphere of 5% CO 2 in air. Following culture, cells in suspension were plated out in flat-bottomed 96-well plates, transferred to 24-well culture dishes and subsequently to a tissue culture flask. Immunophenotyping on cytospins of cultured cells was performed with the alkaline phosphatase and antialkaline phosphatase (APAAP) technique. 13 Monoclonal antibodies used are listed in Table 1 .
DNA extraction and molecular analysis of TCR gene rearrangements
Total DNA from lymph node biopsy, xenografted tumor, blood sample and cultured cells was extracted either from 10 frozen sections (each 10 mm thick) or from 1.0Â10 7 cells as previously described.
14 Table 1 Antibodies used for phenotyping COST cell line, the tumor growing in SCID mouse and the patient's primary tumor Antibodies/Antigens Ag/specificity Cell line/SCID tumor/Patient's tumor
T cells, some histiocytes and some B cells 
Analysis of TcR-g gene rearrangement was performed by using two rounds of multiplex PCR with a set of seven primers, used in two mixes: mix 1 containing VgI consensus in conjunction with Jg2S2, JP and JP1/2 primers, mix 2 containing Vg9.2, Vg10, Vg11, in association with Jg2S2, JP and JP1/2 primers. 15 Analysis of TcR-b gene rearrangement was performed with the three sets of primers, recommended by the European BIOMED-2 collaborative study. 16 The Mix A contains 23 Vb primers and nine Jb primers, the Mix B contains 23 Vb primers and four Jb primers, the Mix C contains two Db primers and 13 Jb primers.
Genomic DNA PCR
The first step was performed from 0.5 mg of genomic DNA per reaction, using NPM primer (5 0 -TCCCTTGGGGGCTTTGA AATAACACC-3 0 , nucleotides 355-380, Accession Number M23613 in the GenBank database) and ALK1 primer (5 0 -GCCAGCAAAGCAGTAGTTGGGGTTG-3 0 , nucleotides 4207-4183, Accession Number NM_004304), with 1.25 U of the Gold Star Taq polymerase (Eurogentec, Angers, France). An amount of 1 ml of the first PCR product was used as a template for the seminested reaction, using NPM and ALK2 (5 0 -GTCGAGGTG CGGAGCTTGCTCAGC-3 0 , nucleotides 4167-4144, Accession Number NM_004304) primers. The amplification consists of a denaturation step at 941C for 20 s, an annealing and elongation step at 681C for 5 min.
RNA extraction and reverse-transcription polymerase chain reaction
Total RNA was extracted from peripheral blood leukocytes and from frozen sections of lymph node biopsy, skin lesion and xenografted tumor using the RNAeasy Midi Kit (Qiagen, Courtaboeuf, France) following the manufacturer's recommendations. Synthesis of the first strand cDNA and PCR amplification were performed in a single tube using the RT-PCR Access Kit (Promega France, Charbonnières, France), following the manufacturer's recommendations. The first step consisted of an ALK gene-specific reverse-transcription at 481C for 45 min, followed by 30 cycles comprising a denaturation step at 941C for 45 s, an annealing step at 641C for 45 s, and an elongation step at 721C for 45 s. This first step was performed using NPM and ALK1 primers. The second round was performed on a 1 ml aliquot from the first amplification, using NPM and ALK2 primers, yielding a PCR product of 177 bp.
Cytogenetic analysis
Cytogenetic analysis was performed from the lymph node after unstimulated 24-h culture. Chromosomes were identified with the RHG-technique and karyotypes were described according to the ISCN-95 nomenclature.
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The cell line was analyzed using both a conventional cytogenetic technique and a multiplex (M-FISH) technique, the latter producing a 24-color karyotyping. The M-FISH was carried out using the SpectraVysion TM system (Vysis) according to the manufacturer's instructions.
Flow cytometry
For surface antigen detection, exponentially growing cells were centrifuged at 400 g for 5 min, washed in PBS and incubated for 30 min at 41C with various primary murine monoclonal antibodies (including CD2, CD3, CD4, CD5, CD7, CD8, CD25 and CD95). After two washes in PBS containing 1% bovine serum albumin and 0.1% sodium azide, fluorescein isothiocyanate (FITC)-coupled goat anti-mouse Ig (Jackson Immunoresearch, West Grove, Pa; 1:50) antiserum was added for 30 min at 41C as the secondary reagent. Cells were then washed twice and fixed in 0.5% formaldehyde. Fluorescence was analyzed on an XL4C Coulter (Beckman Coulter, Hialeah, FL, USA) flow cytometer (excitation wavelength at 488 nm, and emission at 525 nm for FITC).
In one experiment, we also analyzed cell suspensions (1.0 Â 10 7 ) to isolate subpopulations of different cell sizes within the COST cultured cells.
Results
Xenografted tumor cells growth in SCID mice
Cells inoculated subcutaneously into two 8-week-old female SCID mice yielded a tumor in one mouse at the site of injection after 8 weeks.
Histopathology
Except for histiocytes, only present in the lymph node biopsy, the histological features of the tumor growing in SCID mouse and the lymph node lesion were comparable. Indeed, large and small neoplastic cells were observed. However, in the SCID tumor, large and small neoplastic cells were not admixed but rather arranged in two distinct cell populations (Figure 1a and c) .
Immunophenotypical characterization of the tumor
All tumor cells (in the lymph node lesion and in the SCID tumor) coexpressed CD30 and EMA, the staining of the large cells being always stronger than that observed on small cells. ALK1 antibody gave the same pattern in the SCID tumor (Figure 1d ), whereas the opposite was observed in the patient's tumor ( Figure 1b) .
As observed in the patient's lymph node, lymphoma cells were positive for CD43/MT1, perforin, granzyme B and TiA1, but negative for the other T-cell markers (Table 1) .
Cell culture and flow cytometry
The cell line, named COST, established from the xenografted tumor has been maintained in basal ISCOVE medium supplemented with 20% FCS for more than 2 years. Morphologically, cells are predominantly small-sized lymphocytes with only scattered large cells (Figure 1e ). Immunophenotyping performed on cytospins showed an expression of CD30, EMA and CD25 antigens and a cytoplasmic, nucleolar and nuclear staining with ALK1 (Figure 1f) . Both large and small malignant cells were also positive for CD43/MT1 T-cell-associated antigen and cytotoxic markers, that is, perforin, granzyme B and TiA1. Cells were negative for CD2, CD3, CD5, CD7, CD4 and CD8 antigens ( Table 1) .
The results of surface antigens detection by flow cytometry are shown in Table 1 . This technique also revealed that 95% of cells were small sized.
Small-cell variant ALCL cell line L Lamant et al
Molecular analysis
The same TcR-g gene rearrangement was detectable in lymph node biopsy, blood sample, xenografted tumor and cultured cells. As expected PCR products were approximatively of 230 (Mix 1) and 125 bp (Mix 2) (data not shown). A Db-Jb rearrangement was detectable in all samples, using the set C of primers within the expected range of size (182-320 bp).
The genomic DNA-PCR assay gave a band of same size (B1200 bp) in the lymph node biopsy, the xenografted tumor and cultured cells (Figure 2) .
With RT-PCR technique, a band of 177 bp corresponding to NPM-ALK mRNA was detected in the blood sample, the patient's tumor, the tumor growing in SCID mouse, and the cultured cells (data not shown).
Cytogenetic analysis
In the lymph node, 90% of cells showed a standard t(2;5) associated to an extra chromosome X. Karyotype was as follows: 47,XY, þ X,t(2;5)(p23;q35) [20] /46,XY [2] . Karyotype of the cell line showed a clonal evolution characterized by a trisomy of the long arm of chromosome 1. Its karyotype was 48,XY, þ X, þ del(1)(p11p35),t(2;5)(p23;q35) [20] . The M-FISH technique confirmed this interpretation, showing the t(2;5), the extra chromosome X and the extra deleted chromosome 1. This latter was only composed of material from chromosome 1, thus confirming the deletion of the short arm of chromosome 1.
Discussion
It is now largely recognized that ALCL have a wide spectrum of morphological features, since as many as eight morphological variants have been described. 1, [4] [5] [6] [7] 18 However, it is not yet clear whether these morphological variants have prognostic implications, although previous reports have suggested that the small-cell variant cases have some distinctive clinical features. Indeed, involvement of peripheral blood is rare in ALCL, whereas the small-cell variant, which represents only 8% (31/410) of ALCL (G Delsol, personal observations, 2003), may be more frequently associated with a leukemic phase. 5, [19] [20] [21] [22] [23] With the exception of 3 cases reported by Kinney et al, 5 the blood smears show predominantly small-to medium-sized lymphocytes with nuclear irregularities and basophilic cytoplasm. However, these cells may be extremely rare and are easily overlooked on superficial examination as in the present case.
In the present study, the t(2;5)-positive COST cell line was established in culture from a patient's peripheral blood cells, but proved to be difficult to maintain as a permanent cell line. Thus, cells in culture were grafted into SCID mice and the resultant tumor that developed in a SCID mouse allowed the establishment of a permanent cell line, named COST. As expected, the COST cell line, the tumor that grew in the SCID mouse and the patient's primary tumor all demonstrated the same karyotypic anomalies including the t(2;5), all three expressed NPM-ALK protein and shared the same T/NK cytotoxic phenotype
. However, some differences can be noted between the primary tumor and the SCID mouse tumor used to establish the cell line. Indeed, in the lymph node biopsy, large cells were in the minority and Figure 1 Morphological characteristics of malignant cells in the lymph node lesion (a) (H&E, original magnification Â200), the tumor growing in SCID mouse (c) (H&E, original magnification Â200) and the COST cell line (e) (H&E, original magnification Â400). In the lymph node biopsy, large cells are in the minority and scattered throughout the proliferation, while they are organized in two distinct populations in the SCID mouse tumor. Immunoperoxidase labeling of a lymph node section from the patient (b) (original magnification Â200), the paraffin-embedded SCID tumor (d) (original magnification Â200) and the t(2;5) þ cell line (f) (original magnification Â200), with ALK1 antibody. The nuclei, nucleoli and cytoplasms of both large and small cells are strongly labeled by ALK1 in the cell line (f). In the tumor growing in SCID mouse, the staining of the large cells is stronger than that observed on small cells (d), whereas the opposite was observed in the patient's tumor (b). Small-cell variant ALCL cell line L Lamant et al scattered throughout the proliferation or arranged around blood vessels, while they were organized in two distinct populations in the SCID mouse model (Figure 1c ). Although not observed in the diagnostic lymph node biopsy of this case, such an arrangement may be observed in some lymph node biopsies of patients with ALCL (G Delsol, unpublished personal observation). In addition, different morphological subtypes can coexist in the same tumor or can be found at relapse. This is illustrated in our case by the cutaneous involvement consisting only of large cells suggestive of common type variant of ALCL. However, we do not know the factors that are responsible for the morphological transformation from small cells to large anaplastic cells. We are currently investigating the molecular signature of common type ALCL cell lines (ie SU-DHL1 24 and Karpas 299 25 ) vs the gene expression profile of the COST cell line.
To our knowledge, this is the first example of an ALK-positive cell line derived from a small-cell variant of ALCL. Surprisingly, although no tumor cells could be observed by cytological examination in the peripheral blood of the patient, they were undoubtedly present as demonstrated by positive RT-PCR for the t(2;5) and their subsequent growth in cell culture. A few ALCL cell lines have been established so far from ALCL or 'malignant histiocytosis', most of them being ALK þ . [24] [25] [26] [27] [28] [29] [30] Only the FE-PD cell line has been reported as an ALK-negative ALCL cell line. 31 The first cell line reported in the literature was the SU-DHL-1 cell line, established from a pleural effusion of a patient, 24 who presented with a 'diffuse histiocytic lymphoma', but was subsequently reclassified as ALCL according to the REAL classification. 18 The Karpas 299 cell line, which has also been widely studied, was established from a common type ALCL composed of large pleomorphic cells mainly in a sinusoidal distribution. 25 However, the morphological features of the tumors from which the other cell lines are derived have not always been specified, and on occasion are referred to as 'malignant histiocytosis'. [26] [27] [28] 32 Regarding the phenotype of these cell lines, they all express classical activation markers such as CD30, CD25, CD71 and HLA-DR, but their lymphoid lineage is not always clear, with some of them expressing B-or T-cell markers, both T-and B-lineage markers or none. Our cell line could be considered to be of null phenotype since it does not express specific T-cell specific antigens. However, like the neoplastic cells from the primary tumor, it stained positively for the CD43 molecule and for cytotoxic markers such as granzyme B, perforin and TIA-1, which are mainly expressed by NK or cytotoxic T cells. Moreover, the same clonal rearrangement of the TcR-g and TcR-b gene was detected by PCR amplification in the primary biopsy and the SCID mouse tumor, which strongly suggests a T-cell origin for this cell line. Thus, the COST cell line represents the first small-cell variant ALCL cell line that can be used to study the molecular features of this rare morphological variant and should provide further insights into its particular behavior. Moreover, the COST cell line with its dimorphic morphology provides the opportunity to flow cytometrically sort the two cell populations in order to study their functional characteristics and gene expression signatures, possibly providing insights into factors that account for the observed differences in cell size.
